Novitium Pharma's Generic Sulfamethoxazole Receives Approval in the U.S.
Enforcement Report - Week of August 18, 2021
Trimethoprim-sulfamethoxazole with improved lung function in pediatric asthma
Enforcement Report - Week of September 2, 2020
Enforcement Report - Week of May 23, 2018
Enforcement Report - Week of January 17, 2018
Mylan Lab’s Generic Sulfamethoxazole; Trimethoprim Receives Approval In US
Enforcement Report - Week of May 10, 2017
Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on commercializing treatments for urological conditions, today announced that the company has entered into a co-promotion agreement for Primsol® (trimethoprim hydrochloride) oral solution with Allegis Pharmaceuticals, a commercial-stage specialty pharmaceutical company focused on the US pediatric market. Under the agreement, Allegis will exclusively promote Primsol to pediatricians across the U.S. Aytu retains all other rights in the U.S. and around the world and will continue to market the product in urologic indications.